Anzeige
Mehr »
Login
Samstag, 20.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
30 Leser
Artikel bewerten:
(0)

Health Care Sector Stocks Highlight -- Research on OraSure Technologies, DENTSPLY Intl., Sequenom, and BG Medicine

LONDON, June 27, 2014 /PRNewswire/ --

The US markets on Thursday, June 26, 2014 ended on a negative note as the Dow Jones Industrial Average finished at 16,846.13, down 0.13% and the NASDAQ Composite closed at 4,379.05, down 0.02%. The S&P 500 finished the session 0.12% lower at 1,957.22. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 708.54, up 0.06%, with the index advancing 5.43% in the previous three months. Investor-Edge has initiated coverage on the following equities: OraSure Technologies Inc. (NASDAQ: OSUR), DENTSPLY International Inc. (NASDAQ: XRAY), Sequenom Inc. (NASDAQ: SQNM) and BG Medicine Inc. (NASDAQ: BGMD). Free technical research on OSUR, XRAY, SQNM and BGMD can be downloaded upon signing up at:

http://www.investor-edge.com/4276-register

On Thursday, shares in OraSure Technologies Inc. fluctuated between $8.40 and $8.68 before ending the session 0.46% lower at $8.60. The stock reported a trading volume of 0.29 million shares, much below its three months average volume of 0.62 million shares. OraSure Technologies Inc.'s shares have fallen by 0.23% in the previous three trading sessions, while the stock has gained 36.83% in the last one month and 36.72% on YTD basis. The stock is trading above its 50-day and 200-day moving averages of $6.88 and $6.66, respectively. Moreover, shares of OraSure Technologies Inc. have a Relative Strength Index (RSI) of 69.77. Sign up today to read free research on OSUR at:

http://www.investor-edge.com/4276-OSUR-27Jun2014.pdf

On Thursday, shares in DENTSPLY International Inc. edged 0.15% lower, to close the day at $47.95. The stock recorded a trading volume of 0.35 million shares, below its three months average volume of 0.88 million shares. The company shares oscillated between $47.72 and $48.12 during the session. Over the last three trading sessions and over the past one month, DENTSPLY International Inc.'s shares have advanced 0.84% and 2.24%, respectively. However, the stock has fallen by 1.09% since the start of this year. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $46.53 is greater than its 200-day moving average of $46.34. Shares of DENTSPLY International Inc. traded at a PE ratio of 23.93 and have an RSI of 64.12. Sign up today to read free research on XRAY at:

http://www.investor-edge.com/4276-XRAY-27Jun2014.pdf

On Thursday, Sequenom Inc.'s stock recorded a trading volume of 2.34 million shares, higher than its three months average volume of 1.81 million shares. The stock ended the day at $3.78, which was 0.79% below its previous day's closing of $3.81, and registered an intraday range of $3.72 and $3.90. Sequenom Inc.'s stock has surged 5.00% in the previous three trading sessions, 33.57% in the last one month, and 61.54% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $2.96 and $2.56, respectively. Furthermore, Sequenom Inc.'s stock has an RSI of 83.40. Sign up today to read free research on SQNM at:

http://www.investor-edge.com/4276-SQNM-27Jun2014.pdf

BG Medicine Inc.'s stock finished the Thursday's session 1.33% lower at $1.12. A total of 0.24 million shares were traded, which was much below its three months average volume of 1.02 million shares. The stock vacillated between $1.11 and $1.16 during the session. Over the previous three trading sessions, BG Medicine Inc.'s shares have lost 3.04%. However, the company shares have gained 19.56% in the last one month and 7.21% since the beginning of 2014. The stock is trading above its 200-day moving average of $1.08, while the 200-day moving average is below its 50-day moving average of $1.13. Additionally, BG Medicine Inc.'s stock has an RSI of 54.57. Sign up today to read free research on BGMD at:

http://www.investor-edge.com/4276-BGMD-27Jun2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.